Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia

被引:18
|
作者
Gump, J
McGavran, L
Wei, Q
Hunger, SP
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pediat,Sect Pediat Hematol Oncol, Denver, CO 80262 USA
[2] Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA
[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[4] Childrens Hosp, Denver, CO 80218 USA
关键词
TP53; acute lymphoblastic leukemia; children; mutation; relapse;
D O I
10.1097/00043426-200110000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
TP53 is the most commonly mutated gene in human cancer, but TP53 mutations are present in less than 5% of children with acute lymphoblastic leukemia (ALL) at initial presentation. Mutations are detected more frequently in children with relapsed T-cell ALL, but the potential role of TP53 mutations in relapsed B-lineage childhood ALL is not understood as well. The authors determined the nucleotide sequence of amplified DNA from exons 5 to 8 of the TP53 gene in leukemic cells obtained from 17 children with ALL at the time of first bone marrow relapse. All 17 contained only germline TP53 sequences. Review of the published literature disclosed that TP53 mutations have been found in 22% of cases of relapsed ALL. To understand the role of p53 abnormalities in this clinical setting, it will be important for future studies to analyze cases of relapsed ALL with assays capable of interrogating the functional integrity of the p53 pathway.
引用
收藏
页码:416 / 419
页数:4
相关论文
共 50 条
  • [31] Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy
    Alwash, Yasmin
    Kanagal-Shamanna, Rashmi
    Guerra, Veronica A.
    Daver, Naval
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Issa, Ghayas C.
    Borthakur, Gautam
    Loghavi, Sanam
    Takahashi, Koichi
    Yilmaz, Musa
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Kornblau, Steven M.
    Short, Nicholas J.
    BLOOD, 2020, 136
  • [32] Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
    Bories, Pierre
    Prade, Nais
    Lagarde, Stephanie
    Cabarrou, Bastien
    Largeaud, Laetitia
    Plenecassagnes, Julien
    Luquet, Isabelle
    De Mas, Veronique
    Filleron, Thomas
    Cassou, Manon
    Sarry, Audrey
    Fornecker, Luc-Matthieu
    Simand, Celestine
    Bertoli, Sarah
    Recher, Christian
    Delabesse, Eric
    PLOS ONE, 2020, 15 (10):
  • [33] Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Bi, Xia
    French, Zachary
    Kasner, Margaret
    Keiffer, Gina
    Wilde, Lindsay
    Palmisiano, Neil
    BLOOD, 2020, 136
  • [34] IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
    Ibanez, Mariam
    Barragan, Eva
    Roson-Burgo, Beatriz
    Such, Esperanza
    Avetisya, Gayane
    Mora, Elvira
    Liquori, Alessandro
    Sargas, Claudia
    Llop, Marta
    Senent, Leonor
    Vicente, Ana
    Luna, Irene
    Sempere, Amparo
    Andreu, Rafa
    Montesinos, Pau
    Cervera, Jose
    Sanz, Guillermo
    HAEMATOLOGICA, 2020, 105 : 5 - 6
  • [35] Development of TP53 mutations over the course of therapy for acute myeloid leukemia
    Alwash, Yasmin
    Khoury, Joseph D.
    Tashakori, Mehrnoosh
    Kanagal-Shamanna, Rashmi
    Daver, Naval
    Ravandi, Farhad
    Kadia, Tapan M.
    Konopleva, Marina
    Dinardo, Courtney D.
    Issa, Ghayas C.
    Loghavi, Sanam
    Takahashi, Koichi
    Jabbour, Elias
    Guerra, Veronica
    Kornblau, Steven
    Kantarjian, Hagop
    Short, Nicholas J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : 1420 - 1428
  • [36] PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHILDHOOD MEDULLOBLASTOMA
    Pfaff, E.
    Remke, M.
    Sturm, D.
    Witt, H.
    von Bueren, A.
    Wittmann, A.
    Schoettler, A.
    Scheurlen, W.
    Kulozik, A. E.
    Witt, O.
    von Deimling, A.
    Rutkowski, S.
    Hawkins, C.
    Tabori, U.
    Lichter, P.
    Korshunov, A.
    Pfister, S. M.
    NEURO-ONCOLOGY, 2010, 12 (06) : II3 - II3
  • [37] TP53 mutated acute myeloid leukemia
    Sill, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 257 - 257
  • [38] Characterization of chronic myelomonocytic leukemia with TP53 mutations
    Wang, Wei
    Routbort, Mark J.
    Loghavi, Sanam
    Tang, Zhenya
    Medeiros, L. Jeffrey
    Wang, Sa A.
    LEUKEMIA RESEARCH, 2018, 70 : 97 - 99
  • [39] Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations
    Wang, Wei
    Routbort, Mark
    Loghavi, Sanam
    Tang, Zhenya
    Medeiros, L. Jeffrey
    Wang, Sa
    MODERN PATHOLOGY, 2018, 31 : 563 - 563
  • [40] Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations
    Wang, Wei
    Routbort, Mark
    Loghavi, Sanam
    Tang, Zhenya
    Medeiros, L. Jeffrey
    Wang, Sa
    LABORATORY INVESTIGATION, 2018, 98 : 563 - 563